Common side effects of Tucatinib and management suggestions

Common side effects of Tucatinib and management suggestions

Like other medications, Tucatinib may cause side effects, but not everyone will experience them. Very common side effects (occurring in more than 10% of patients) include: diarrhea, nausea, vomiting, mouth ulcers or oral mucositis, abnormal liver function (which may present as yellowing of the skin and eyes, dark urine, pain in the upper right abdomen), rash, joint pain, weight loss, and nosebleeds. Among these, diarrhea and liver injury are key events requiring monitoring. If any of these symptoms occur, inform your doctor promptly. Depending on the severity of side effects, your doctor may recommend temporarily stopping the medication, reducing the dose, or providing symptomatic supportive care (e.g., antiemetics, liver-protective agents) to ensure treatment can continue safely.

Key considerations for combination therapy of Tucatinib with Trastuzumab and Capecitabine

Tucatinib is not used alone but must be combined with two other anticancer drugs, Trastuzumab and Capecitabine, as part of a treatment regimen. This means patients need to manage the timing and side effects of all three medications simultaneously. Trastuzumab is usually given by intravenous infusion or subcutaneous injection, while Capecitabine and Tucatinib are both oral drugs. Patients should read the prescribing information for each drug separately and strictly follow the dosage and frequency requirements for each as directed by the doctor. Because the combination may cause overlapping or intensified side effects (such as diarrhea, nausea, hand-foot syndrome, etc.), patients need to monitor physical changes more closely. It is recommended to use a medication log or cell phone alarms to remind you to take your medications, and proactively report all discomforts to your doctor during follow-up visits, so the doctor can differentiate which drug is causing the adverse reaction and adjust the regimen precisely.

Special considerations for patients with renal impairment or dietary restrictions

The prescribing information clearly states that each 300 mg dose of Tucatinib contains 60.6 mg of potassium and 55.3 mg of sodium. For people with normal kidney function, these amounts are generally not a concern. However, if you have chronic kidney disease, renal impairment, or are on a low-potassium or low-sodium diet (e.g., due to hypertension, heart failure, or kidney disease), special attention is required. Additional potassium intake may increase the burden of renal excretion and lead to hyperkalemia; additional sodium intake may affect blood pressure and fluid balance. Before starting Tucatinib, you should proactively inform your doctor of your glomerular filtration rate, blood electrolyte levels, and current dietary restrictions. Your doctor may recommend more frequent monitoring of blood potassium, blood sodium, and kidney function, and adjust your diet or Tucatinib dosage if necessary.